Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines
Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines
复制标题
DOI：
10.1002/mpo.1242
复制
发表时间：
2001-12-01
期刊：
影响因子：
--
通讯作者：
Ambros, IM
中科院分区：
文献类型：
--
作者：
Ambros, PF;Ambros, IM
本文提出的关于肿瘤和骨髓处理的分子生物学、分子遗传学和免疫学标记物的评估建议是由SIOP欧洲神经母细胞瘤病理生物学和骨髓小组制定的。尽管这些指南是针对神经母细胞瘤(神经母细胞瘤、神经节细胞瘤和神经节神经瘤)制定的，但它们也适用于所有其他肿瘤实体。本文分为三个主要部分。病理学指南概述了在可切除和不可切除的神经母细胞瘤的情况下，肿瘤材料的处理、切片和固定。该指南包括切开活检、经切活检、细针抽吸和骨髓抽吸。强调了病理评估对于解释分子遗传学和分子生物学结果的重要性，其中也包括对肿瘤细胞含量的准确测定。此外，还对细胞毒治疗后获得的肿瘤材料、免疫组织学和免疫细胞学问题以及淋巴结检查提出了建议。在生物学指南中，讨论了MYCN、染色体1p36调查和DNA含量测量的不同方法，并推荐使用DNA探针。此外，还介绍了SIOP欧洲神经母细胞瘤组中已经使用的具体定义和通用术语。在骨髓指南中，给出了关于要使用的方法的建议，并展示了最重要的陷阱。希望标准化方法的使用和共同语文的应用都将有助于提高所收集数据的质量和可靠性，从而提高研究报告之间的可比性。这些改进应该被证明对受影响的患者非常有价值。
The recommendations concerning tumor and bone marrow handling for the evaluation of molecular-biologic and molecular-genetic and immunologic markers presented in this paper were developed by the SIOP Europe Neuroblastoma Pathology and Biology and Bone Marrow Group. Although the Guidelines were developed for neuroblastic tumors (neuroblastoma, ganglioneuroblastoma and ganglioneuroma), they are applicable to all other tumor entities as well. The paper is subdivided in three main parts. The Pathology Guidelines give an overview about the handling, sectioning and securing of tumor material in case of resectable and non-resectable neuroblastic tumors. The Guidelines encompass open biopsies, tru cut biopsies, fine needle aspirations, and bone marrow aspiration. The importance of the pathologic evaluation for the interpretation of the moleculargenetic and molecular-biologic results, which also includes the exact determination of the tumor cell content is stressed. Besides this, recommendations concerning tumor material obtained after cytotoxic therapy, immunohistologic and immuno-cytologic issues and lymph node examination are addressed. In the Biology Guidelines, the different methods for MYCN, chromosome 1p36 investigations and DNA content measurements are discussed and DNA probes are recommended. Furthermore, specified definitions and a common terminology already used in the SIOP Europe Neuroblastoma Group are presented. In the Bone Marrow Guidelines, recommendations concerning the methods to be employed are given and the most important pitfalls are demonstrated. Both the use of standardized methods and the application of a common language will, it is hoped, contribute to the quality and reliability of collected data and thus to a better comparability between and among research reports. These improvements should prove to be of great value for the affected patients.